通过管理高甘油三酯血症预防动脉粥样硬化性心血管疾病。

Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.

作者信息

Brinton Eliot A

机构信息

Atherometabolic Research, Utah Foundation for Biomedical Research, 419 Wakara Way, Suite 211, Salt Lake City, UT 84108, USA.

出版信息

Cardiol Clin. 2015 May;33(2):309-23. doi: 10.1016/j.ccl.2015.02.007.

DOI:10.1016/j.ccl.2015.02.007

PMID:25939302

Abstract

Mendelian randomization data strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease (ASCVD), and so triglyceride (TG) level-lowering treatment in HTG is now more strongly recommended to address the residual ASCVD risk than has been the case in (generally earlier) published guidelines. Fibrates are the best-established agents for TG level lowering and are generally used as first-line treatment of TG levels greater than 500 mg/dL. Statins are the best-established agents for ASCVD prevention, and so are usually used as first-line treatment of TG levels less than 500 mg/dL.

摘要

孟德尔随机化数据有力地表明，高甘油三酯血症（HTG）会引发动脉粥样硬化性心血管疾病（ASCVD），因此，相较于（通常更早发布的）指南，现在更强烈推荐对HTG进行降低甘油三酯（TG）水平的治疗，以解决残留的ASCVD风险。贝特类药物是已确立的最佳降低TG水平的药物，通常用作TG水平大于500mg/dL的一线治疗药物。他汀类药物是已确立的最佳预防ASCVD的药物，因此通常用作TG水平小于500mg/dL的一线治疗药物。